A Pharmaceutical Strategies Group survey finds employers and health plans prioritizing cost control and cross-benefit management, with growing willingness to trade rebates for stronger utilization oversight amid rising complexity and CGT concerns.
"These priorities... should be a wake-up call for many health care stakeholders who think the status quo is acceptable and that the days of blank checks will never end," said Elizabeth Mitchell, president and CEO of the Purchaser Business Group on Health (PBGH).
Employee demand for GLP-1s continues to surge as prices are primed to start lowering, prompting many orgs to rethink plan design to balance employee expectations and costs.
